Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199902 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5986521 | 0.98 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5986529 | 0.98 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5987170 | 0.98 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL15307680 | 0.87 | GABRA1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL5987166 | 0.86 | CYP2D6 (0.34) | HTR2AHTR2CHTR2B | |
| SCHEMBL5986488 | 0.84 | SLC6A4 (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL5988412 | 0.84 | HTR2A (0.41) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5987973 | 0.83 | SLC6A4 (0.37) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL7789432 | 0.83 | SLC6A4 (0.37) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. | 2013-10-10 | — | — | US | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267500-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ADRA2C, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.